Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab in PD-L1+ Advanced Urothelial Bladder Cancer
NCT04004221Phase 2Completed
- Sponsor
- BeiGene
- Start
- Jun 2017
- Primary completion
- Sep 2019
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of tislelizumab in Urothelial Bladder Cancer (UBC), sponsored by BeiGene. Started Jun 2017; status: completed.
02
Drugs
tislelizumab
03
Conditions
Urothelial Bladder Cancer (UBC)
Beyond the preview
Go deeper on NCT04004221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04004221.